Gabapentin for Alcohol Relapse Prevention in a Patient With a Gabapentinoid Misuse History
A woman in stable opioid-use-disorder remission wants to try gabapentin for persistent drinking. She’s also the one who brought up, unprompted, that she once misused that exact drug combined with an opioid.
S.B. calls it “the safer swap” — her own phrase for what happened eighteen months ago, when evenings that used to end in reaching for opioids started ending in a drink instead, and she told herself the substitution made her safer rather than admitting it was still a problem. She is thirty-six, and has opioid use disorder in sustained remission on buprenorphine-naloxone for two years now, stable and adherent, following a period roughly four years ago when she combined prescription oxycodone with gabapentin specifically for the amplified high the combination produced — a history she has never hidden from her treatment team and is candid about again today. Three weeks ago she got her membership back at the community ceramics studio, the first hobby she's returned to since her life narrowed down to almost nothing but managing what she now describes as two separate addictions, one substituting for the other rather than either actually resolving.
Her alcohol use disorder hasn't responded fully to what's been tried: naltrexone was never an option given her buprenorphine maintenance, since combining an antagonist with her partial agonist would defeat the maintenance entirely, and acamprosate, taken faithfully for five months, blunted her drinking somewhat but left the craving present most evenings — particularly, she's noticed, around the same hours she used to use opioids, which she reads as more than coincidence. She has no liver or kidney disease, and her most recent urine toxicology, drawn as part of routine buprenorphine monitoring, was clean apart from the expected buprenorphine itself.
Gabapentin came up in her own reading before this visit, and she raised it herself rather than waiting to be asked — aware of, and visibly anxious about, her own history with the drug, wanting an honest answer more than reassurance.
The drug with real efficacy data and a history that names it specifically
Mason's randomized trial found a real dose-response effect — 17.0% abstinent at 1800 mg a day versus 4.1% on placebo, with corresponding improvements in heavy drinking days. She's been stable on buprenorphine for two years with no aberrant use, and she brought this question to us herself, disclosing her own history unprompted. That's not the profile of someone we should assume will misuse a second controlled substance just because she once did.
I want to name the specific warning here, not a general caution about controlled substances. The FDA issued a safety communication specifically about gabapentinoids combined with opioids, including buprenorphine, raising real risk of serious respiratory depression. That's not a hypothetical risk category for her — it's the exact combination she has a documented history of using deliberately, for the amplified effect the combination produces.
Her two years of stability matter, but they don't erase the specific pharmacologic risk of putting gabapentin back into a regimen that already includes an opioid, however well-managed that opioid currently is.
I don't think we have to choose between trusting her and taking the interaction risk seriously. Her disclosing this herself, before we asked, is itself real clinical information — it's the opposite of the concealment pattern that usually accompanies active misuse. I'd offer a trial at a conservative starting dose, well below 1800 mg initially, dispensed in limited quantities with structured refill visits, and named explicitly with her as a decision we're making together because of her history, not despite ignoring it.
Agreed: a conservative, slowly titrated gabapentin trial with limited dispensing and frequent structured follow-up, named openly with S.B. as a decision made because of, not despite, her history.
Not agreed: whether this combination should have been offered at all given the FDA's specific warning, or whether the structured-dispensing compromise adequately addresses that risk. The clinical pharmacologist remains uneasy about the respiratory-depression signal regardless of dispensing controls and asked that this be documented as a standing concern, not a resolved one; the addiction psychiatrist views the safeguards as sufficient given her demonstrated stability. S.B. herself said she'd rather have the honest disagreement on record than a falsely reassuring yes.